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Acute-on-chronic liver failure (ACLF) is a recently recognized syn-
drome characterized by acute decompensation (AD) of cirrhosis
and organ/system failure(s) (organ failure: liver, kidney, brain,
coagulation, circulation and/or respiration) and extremely poor
survival (28-day mortality rate 30–40%). ACLF occurs in relatively
young patients. It is especially frequent in alcoholic- and untreat-
ed hepatitis B associated-cirrhosis, in addition it is related to bac-
terial infections and active alcoholism, although in 40% of cases
no precipitating event can be identiﬁed. It may develop at any
time during the course of the disease in the patient (from com-
pensated to long-standing cirrhosis). The development of ACLF
occurs in the setting of a systemic inﬂammation, the severity ofJournal of Hepatology 20
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Systemic inﬂammation may cause ACLF through complex
mechanisms including an exaggerated inﬂammatory response
and systemic oxidative stress to pathogen- or danger/damage-as-
sociated molecular patterns (immunopathology) and/or alter-
ation of tissue homeostasis to inﬂammation caused either by
the pathogen itself or through a dysfunction of tissue tolerance.
A scoring system composed of three scores (CLIF-C OFs, CLIF-C
AD, and CLIF-C ACLFs) speciﬁcally designed for patients with
AD, with and without ACLF, allows a step-wise algorithm for a
rational indication of therapy. The management of ACLF should
be carried out in enhanced or intensive care units. Current
therapeutic measures comprise the treatment for associated
complications, organ failures support and liver transplantation.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Cirrhosis has long been recognized by the development of acute
deterioration of liver and/or renal function, hepatic encephalopa-
thy and high risk of hospital mortality in association to a pre-
cipitating event, commonly an infection [1–3]. During the last
decade many experts have suggested that this array of symptoms
may constitute the hallmark of a new speciﬁc entity. The term
acute-on-chronic liver failure (ACLF) has gained popularity for
this condition [4–6]. Since current diagnostic criteria of ACLF
are based on personal opinions rather than on objective data, sig-
niﬁcant discrepancies between groups are apparent [7–9]. Due to
these discrepancies, the ﬁrst project of EASL-Chronic Liver Failure
(CLIF) Consortium was to perform a prospective observational
investigation (CANONIC Study) in a large series of patients with
cirrhosis (1343 cases). These patients were consecutively admit-
ted to 21 European hospitals for the treatment of an acute
decompensation (AD). The aim was to assess the concept, preva-
lence, diagnostic criteria, precipitating events, natural course and
prognosis of ACLF. The current review is largely based on this
investigation [10,11].15 vol. 62 j S131–S143
ReviewKey Points 1
• ACLF is a specific syndrome characterized by acute 
decompensation (AD), organ failure (OF) and high 
short-term mortality. AD means development of ascites, 
encephalopathy, gastrointestinal hemorrhage and/or 
bacterial infections. OFs (liver, kidney, brain, 
coagulation, respiration, circulation) are defined by 
the original CLIF-SOFA score or its simplified version 
CLIF-C OF score. High short-term mortality means a 
28-day mortality rate ≥15%
• Patients with single OF have different 28-day mortality 
according to the type of OF and the presence of 
renal dysfunction (serum creatinine 1.5-1.9 mg/
dl) and/or cerebral dysfunction (grade 1-2 hepatic 
encephalopathy). 1. Patients with liver, coagulation, 
respiration or circulation failure and no cerebral and/
or renal dysfunction have low mortality rate (5-7%) 
and therefore no ACLF; 2. Patients with cerebral 
failure (grade 3-4 hepatic encephalopathy) but no 
renal dysfunction also have low mortality (8%) and 
no ACLF; 3. Finally, patients with renal failure (serum 
creatinine ≥2 mg/dl), those with cerebral failure and 
renal dysfunction, and those with liver, coagulation, 
respiration or circulation failure, and renal and/or 
cerebral dysfunction have a mortality rate of 16-30% 
and ACLF. The presence of one OF is, therefore, not a 
synonym of ACLF
• Mortality in ACLF correlates with the ACLF grade: 
ACLF-1 is associated to a 28-day mortality rate of 22%,  
ACLF-2 (2 OFs) of 32% and ACLF-3 (3-6 OFs) of 73%. 
Mortality rate in patients without ACLF is 4.9%
• The prevalence of ACLF in patients hospitalized with 
AD is 30%, being particularly prevalent in alcoholic 
and hepatitis B associated cirrhosis. ACLF may 
develop at any time during the course of cirrhosis and 
is especially severe in patients without prior history of 
AD. The most frequent precipitating events associated 
to ACLF are bacterial infections, active alcoholism or 
acute reactivation of hepatitis B, but in 40% of cases no 
precipitating event can be identified
• ACLF is very dynamic. It may improve (50%) or worsen 
(20%) within a short period of time. Not surprisingly, 
prognosis is more dependent on the early clinical 
course than of the initial ACLF gradeDeﬁnition, prevalence, clinical features and prognosis of ACLF
according to the CANONIC study
Methodology used
The following features were pre-deﬁned before the analysis of
the CANONIC database:
1. ACLF was deﬁned as a syndrome characterized by AD of cir-
rhosis associated to organ failure (OF) and high short-term
mortality rate.S132 Journal of Hepatology 20152. AD refers to the acute development of ascites, hemorrhage,
encephalopathy and/or bacterial infections.
3. The sequential Organ Failure Assessment (SOFA) Scale [12]
was the model selected for the diagnosis of organ failure
because it is widely used in patients requiring intensive care
treatment and is superior to the Child-Pugh and MELD scores
[13–15] in predicting mortality in patients with cirrhosis and
(OF(s)). Since components of the SOFA score (liver, renal,
cerebral, coagulation, circulatory and respiratory function)
do not take into account speciﬁc features of cirrhosis, the
SOFA scale was modiﬁed establishing a new scale called
the CLIF-SOFA score (CLIF-SOFAs) adapted for liver patients.
A simpliﬁed CLIF-SOFA score (CLIF Consortium Organ
Failure score, CLIF-C OFs) with identical diagnostic criteria
for organ failure and similar prognosis was later designed
(Fig. 1A) [16].
4. ‘‘Relatively high short-term mortality rate’’ was deﬁned as a
mortality rate equal or greater than 15% within a period of
28 days. This ﬁgure represents approximately 50% of the
short-term mortality rate associated with severe sepsis in
the general population [17]. The inclusion of a short-term
mortality rate threshold in the deﬁnition of ACLF was consid-
ered important because it has major therapeutic implica-
tions. Fig. 1B shows that mortality rate in the CANONIC
patients was clearly related to the presence and number of
organ failures as deﬁned by the CLIF-SOFA score or by the
CLIF-C OFs. Also, renal dysfunction (as deﬁned by a serum
creatinine of 1.5–1.9 mg/dl) and/or moderate (grade 1–2)
hepatic encephalopathy (cerebral dysfunction), when associ-
ated to single organ failure, were found to predict prognosis.
Based on the presence of OF, renal and/or cerebral dysfunc-
tion, and short-term mortality rate, the following groups of
patients were excluded and included from the diagnosis of
ACLF:
1. Excluded: (a) No OF; (b) Single non-renal OF with serum
creatinine <1.5 mg/dl and no hepatic encephalopathy.
2. Included: (a) Single renal failure; (b) Single non-renal OF
plus renal dysfunction and/or grade 1–2 hepatic
encephalopathy; (c) 2 or more OFs.Severity of ACLF was then graded according to the number of
OFs: ACLF 1: 1 OF; ACLF 2: 2 OFs; ACLF 3: 3–6 OFs.
The prevalence of ACLF in the CANONIC Study patients was
30% (20% at admission and 10% during hospitalization) and
the overall 28-day and 90-day mortality rates were 33% and
51%, respectively. Mortality rates in patients without ACLF
were low (28-day: 1.9%; 90-day: 10%). The prevalence, 28-
day and 90-day mortality rates associated with the different
grades of ACLF were 15.8%, 22%, and 41% respectively in
ACLF-1, 10.9%, 32%, and 55% in ACLF-2 and 4.4%, 73%, and
78% in ACLF-3.
Clinical features and precipitating events of ACLF
Patients with ACLF were signiﬁcantly younger than those
without ACLF and the main etiologies were alcoholism in
60%, hepatitis C in 13% and alcoholism plus hepatitis C in
10% (Table 1). In only 5% of patients was cirrhosis associated
with hepatitis B virus (HBV) infection. The commonest OF in
patients with ACLF was renal failure (56%), followed by liver,vol. 62 j S131–S143
Organ system
Liver, bilirubin (mg/dl)
Kidney, creatinine (mg/dl)
Brain, grade (West-Haven)
Coagulation, INR
Circulation, MAP (mmHg)
Respiratory PaO2/FiO2
or SpO2/FiO2
Score = 1
<6
<2
0
<2.0
≥70
>300
>357 
Score = 2
6-≤12
2-<3.5
1-2
2.0-<2.5
<70
≤300 and >200
>214 and ≤357
Score = 3
>12
≥3.5 or renal 
replacement
3-4
≥2.5
Vasopressors
≤200
≤214
Number and types 
of organ failures  
No kidney 
dysfunction and no 
mild-to-moderate 
hepatic 
yhtapolahpecne
Kidney dysfunction 
and/or 
mild-to-moderate 
hepatic 
encephalopathy
No organ failure 20/562 (3.6) 19/312 (6.2) 
Single liver failure 4/68 (5.9) 10/33 (30.3) 
Single cerebral failure 2/25 (8.0) 1/5 (20.0) 
noitalugaocelgniS
failure 1/19 (5.3) 2/9 (22.2) 
Single circulation or 
single lung failure 1/15 (6.7) 2/7 (28.6) 
Single kidney failure 9/57 (15.8) 7/29 (24.1) 
Two organ failures 19/66 (28.8) 12/31 (38.7) 
Three organ failures 
or more 25/59 (86.2) 8/13 (61.5) 
A
B
Fig. 1. CLIF Consortium organ failure score and mortality according to type
of organ failure. (A) CLIF Consortium Organ Failure Score. The highlighted area
in light blue reﬂects the deﬁnition of each organ/system failure. (B) 28-day
mortality in patients included in the CANONIC Study classiﬁed according to the
number of organ failures and the presence or absence of kidney dysfunction
and/or grade I–II hepatic encephalopathy. The highlighted area in light blue
shows the subgroups of patients deﬁned as having ACLF (with organ failure(s)
and a 28-day mortality rate >15%). Kidney dysfunction: serum creatinine 1.5–
1.9 mg/dl. In brackets: % of 28-day mortality. MAP, mean arterial pressure; FiO2,
fraction of inspired oxygen; PaO2, partial pressure of arterial oxygen; SpO2,
pulse oximetric saturation.
JOURNAL OF HEPATOLOGYcoagulation, cerebral, circulatory and respiratory failures (44%,
28%, 24%, 17%, and 9%, respectively). The prevalence of circu-
latory and respiratory failure was signiﬁcant only in patients
with ACLF-3. Patients with ACLF showed systemic inﬂamma-
tion (high count of C-reactive protein and leukocyte concen-
tration) which was independent on the presence or absence
of recognized bacterial infections.
The traditional concept that OF(s) and, therefore, ACLF is the
ﬁnal event of a long-standing decompensated cirrhosis was not
supported by the CANONIC Study, since almost half of patients
with ACLF did not have a prior history of AD or had developed
the ﬁrst AD within the 3 months prior to diagnosis of ACLF
(Table 1). Patients with no history of decompensated cirrhosis
developed a more severe form of ACLF than patients with previ-
ous episodes of decompensation (28-day mortality of 42% vs.
29%).
The most common precipitating events were bacterial
infections and active alcoholism (Table 1). Interestingly inJournal of Hepatology 2015patients with ACLF the prevalence of alcoholic cirrhosis
(60%) was higher than the prevalence of active alcoholism,
indicating that alcoholic hepatitis accounts for only part of
cases of ACLF associated with alcoholic cirrhosis. There was
a small proportion of other precipitating events. As a trigger,
gastrointestinal hemorrhage was less frequent in patients with
ACLF than in patients without ACLF, suggesting that hemor-
rhage, if not associated to other complications (i.e. active
drinking and/or bacterial infections), is not related to ACLF
development. Finally, and of considerable interest is the sig-
niﬁcant proportion of patients developing ACLF in the absence
of any identiﬁable trigger. Mortality was independent of the
presence and type of precipitating events, indicating that
although triggers are important in the development of ACLF,
mortality depends of other factors, such as the clinical course
(see below) and number of OFs.
Clinical course of ACLF
ACLF is an extraordinarily dynamic syndrome [11] and only one-
third of ACLF patients grade had no change during hospitaliza-
tion. In most cases ACLF either improved (50%) or worsened
(20%). Resolution of ACLF (no OF) was observed in 40% of
patients. The frequency of resolution was high (55%) in patients
with ACLF-1, moderate (35%) in patients with ACLF-2 and low
(15%) in patients with ACLF-3. Although the ACLF grade at diag-
nosis correlated with prognosis, the clinical course of the syn-
drome during hospitalization was the most important
determinant of short-term mortality. In fact, 28-day survival in
patients developing resolution of ACLF was similar than that in
patients with AD without ACLF. Since changes in ACLF grade
occurred very rapidly (1–2 days) or rapidly (3–7 days) in most
patients, the early course of ACLF was a major determinant of
prognosis.
ACLF in patients with cirrhosis associated to HBV infection
Li et al. have reported the characteristics of ACLF in 890
consecutive patients with HBV associated-cirrhosis and AD
using the diagnostic criteria derived from the CANONIC
Study [18]. Their results indicate that ACLF associated to
HBV infection is similar to ACLF associated to alcoholism
or chronic hepatitis C although with some speciﬁc character-
istics. The prevalence of ACLF in the Chinese study was
higher (40%) than in the CANONIC series, with ACLF-2 being
the most frequent ACLF grade, followed by ACLF 1 and 3.
Liver and coagulation failures were the most common OFs.
The most frequent precipitating event was bacterial infec-
tions followed by reactivation of hepatitis B and active alco-
holism. In half of patients no precipitating event could be
identiﬁed. As in the CANONIC Study, patients with ACLF
showed systemic inﬂammation independently on the type
of precipitating event. Mortality rates (28-day and 90-day)
in patients with no ACLF, ACLF and ACLF grades 1, 2, and
3 were similar to those in CANONIC series. Fifty-per-cent
of patients had no prior AD episodes. Mortality was unrelat-
ed to the presence or type of precipitating events or prior
history of AD.vol. 62 j S131–S143 S133
Table 1. Characteristics of patients with or without ACLF.
Characteristic No ACLFa (N = 871) ACLF (N = 417) p value
Age (yr) 58.1 ± 12.3 55.8 ± 11.7 0.0011
Male sex 551 (63.3) 267 (64.0) 0.7887
Ascites 533 (61.4) 289 (80.7) <0.001
Mean arterial pressure (mmHg) 84.8 ± 11.9 78.4 ± 13.1 <0.001
Cause of cirrhosis 
Alcohol 398 (48.5) 233 (58.4) 0.0011
Hepatitis C virus 182 (22.2) 59 (14.8) 0.0024
Alcohol plus hepatitis C virus 76 (9.3) 37 (9.3) 0.9927
Potential precipitating events of ACLF 
Bacterial infection 218 (25.2) 160 (39.1) <0.001
Gastrointestinal hemorrhage 99 (15.6) 74 (17.8) 0.3505
Active alcoholism within the last 3 monthsb 115 (13.9) 89 (22.9) <0.001
Other precipitating eventc 31 (3.8) 38 (9.6) <0.001
No precipitating eventd 483 (64.8) 124 (43.1) <0.001
More than one precipitating evente 41 (28.7) 25 (29.8) 0.8613
Organ failures
Liver 51 (7.9) 156 (39.6) <0.001
Kidney 0 (0) 196 (49.8) <0.001
Cerebral 13 (2.0) 87 (22.1) <0.001
Coagulation 14 (2.2) 122 (31.0) <0.001
Circulation 10 (1.6) 89 (22.6) <0.001
Lungs 3 (0.5) 50 (12.7) <0.001
Kidney dysfunctionf 68 (7.8) 69 (16.6) <0.001
Mild-to-moderate hepatic encephalopathyg 221 (25.4) 173 (41.6) <0.001
Laboratory data
Hematocrit (%) 32 ± 6 28 ± 5 <0.001
Platelet count (x109/L) 110 ± 75 95 ± 71 0.0011
Serum bilirubin (mg/dl) 4.3 ± 5.0 11.7 ± 11.4 <0.001
International normalized ratio 1.5 ± 0.4 2.1 ± 0.9 <0.001
Alanine aminotransferase (U/L) 54 ± 130 72 ± 126 0.0326
Aspartate aminotransferase (U/L) 90 ± 141 198 ± 716 <0.001
γ-Glutamyltransferase (U/L) 174 ± 298 130 ± 158 0.0019
Serum creatinine (mg/dl) 0.9 ± 0.3 2.0 ± 1.4 <0.001
Serum sodium (mmol/L) 135.7 ± 5.3 134.5 ± 6.6 0.0013
Time from first previous decompensation 
No previous decompensation 237 (29.8) 98 (26.4) 0.2419
Less than 3 months 85 (10.7) 58 (15.6)
0.0967From 3 to 12 months 139 (17.5) 62 (16.7)
More than 12 months 334 (42.0) 153 (41.2)
Data are means ± SD or number of patients (%).
aAbsence or presence of ACLF at enrolment or during the post-enrolment hospitalization.
bActive alcoholism was deﬁned by more than 14 drinks per week in women and more than 21 drinks per week in men.
cOther precipitating event was deﬁned by the presence of one of the following: transjugular intrahepatic porto-systemic shunting, major surgery, therapeutic paracentesis
without use of intravenous albumin, hepatitis, or alcoholic hepatitis (liver biopsy required for diagnosis).
dNo precipitating event denotes the absence of bacterial infection, active alcoholism, or other precipitating event.
eMore than one precipitating event denotes the presence of at least two of these: bacterial infection, active alcoholism, or other precipitating event.
fKidney dysfunction was deﬁned by serum creatinine levels ranging from 1.5 mg/dl to 1.9 mg/dl.
gMild-to-moderate hepatic encephalopathy is grade I or II hepatic encephalopathy according to the West Haven classiﬁcation.
ReviewSystemic inﬂammation as a cause of ACLF
As indicated, white cell count and plasma C-reactive protein
(CRP) levels are higher in patients with ACLF than in thoseS134 Journal of Hepatology 2015without, indicating higher degree of systemic inﬂammation in
the former patients [4]. Furthermore, the higher white cell
count or CRP levels the higher the number of failing organs
[4]. Together these ﬁndings suggest that OFs may result fromvol. 62 j S131–S143
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an excessive inﬂammatory response, for which the term immu-
nopathology is used [19]. As shown by studies in type-1
hepatorenal syndrome, a special form of ACLF, and in severe
sepsis, immunopathology may cause OF as a consequence of
impairment in cardiocirculatory function leading to organ
hypoperfusion and/or by direct speciﬁc effect of inﬂammatory
mediators on cell function and death. An alternative view is that
OFs develop mainly because of an impairment of mechanisms
involved in tissue homeostasis. The distinction between these
two arms of the alternative is crucial, for example in the context
of infection. If an excessive immune response to the pathogen is
the cause of OF, the use of anti-inﬂammatory therapies could be
effective. In contrast, if the primary mechanism of OF is an
alteration of tissue homeostasis caused directly by the patho-
gen, the use of anti-inﬂammatory therapies may decrease the
immune response (which is in fact beneﬁcial to reduce patho-
gen burden), fail to restore tissue homeostasis and ﬁnally wors-
en the outcome of the infection.
Key Points 2
• In 30% of cases of ACLF, inflammation develops in 
response to bacterial infection. Infection-related ACLF 
represents 30% of cases of ACLF. Whole bacteria 
exhibit different pathogen-associated molecular 
patterns (PAMPs) that are specifically recognized by 
pattern-recognition receptors (PRRs) expressed in 
innate immune cells. During the first hours of infection, 
recognition of PAMPs by PRRs results in the induction 
of hundreds of genes including those coding for pro-
inflammatory cytokines. Induction of these cytokines 
is excessive in patients with ACLF resulting in the 
development of tissue damage (a process called 
immunopathology) and subsequent multiorgan failure
• Tissue damage in infection-related ACLF may involve 
mechanisms others than immunopathology. Bacteria 
may directly damage host tissue by altering a broad 
variety of cell functions. Tissue damage may also be 
related to failed tolerance; i.e. failure of “endurance” 
mechanisms that normally protect tissue against direct 
tissue damage by bacteria and immunopathology
• A significant number of cases of ACLF are not related to 
obvious bacterial infection. Nevertheless, in these cases 
an excessive immune host response probably causes 
tissue damage and OFs. The excessive 
immune response may be triggered by PAMPs released 
by bacteria that have been killed after their translocation 
from the intestinal lumen. Alternatively the excessive 
immune response may be a result of PRR activation 
by endogenous (non bacterial) molecules released 
by dying cells (e.g. the danger-associated molecular 
pattern called high-mobility group box 1, known as 
HMGB1). All these mechanisms are pro-inflammatory
• Studies are needed to decipher mechanisms of OFs
in ACLFJournal of Hepatology 2015The paradigm of bacterial infections. Bacterial infections in the general
population
Early stage
Initiation of inﬂammation. Bacteria express molecular structures
known as pathogen-associated molecular patterns (PAMPs) that
are speciﬁcally recognized by germ line-encoded receptors called
pattern-recognition receptors (PRRs) located at the surface or
within innate immune cells (Table 2) [20,21]. Among PRRs there
are toll-like receptors (TLRs), NOD-like receptors (NLRs), retinoic
acid-inducible gene (RIG)-I-like receptors (RLRs) (Table 2). The
engagement of PRRs results in the activation of signaling cascades
that activate transcription factors (e.g., nuclear factor (NF)-jB,
AP-1, interferon (IFN)-regulator factor (IRF) 3, among others)
[20,21]. These induce hundreds of genes including those encod-
ing major inﬂammatory cytokines [7,22,23] (Fig. 2A and B). This
inﬂammatory response is beneﬁcial in that it plays a major role
in host resistance to infection, i.e. the reduction of bacterial bur-
den [19]. However, the inﬂammatory response to bacterial com-
ponents may be excessive and associated with collateral tissue
damage (immunopathology) resulting in OF [19].
Effects of an excessive inﬂammatory response. Patients with this
excessive response have severe sepsis or septic shock [20].
Bacterial components and proinﬂammatory cytokines are known
to induce the inducible nitric oxide (NO) synthase in arteriolar
walls of the systemic circulation and on cardiac tissue resulting
in increased production of the vaso-relaxant NO, impairment in
cardiac inotropic function, arterial hypotension and decreased
oxygen delivery to tissues [20,24]. Bacterial components and
proinﬂammatory cytokines target the endothelium of microvas-
culature in vital organs favoring the formation of microthrombi
(and tissue hypoxia) as well as adhesion and transendothelial
migration of various circulating cells [25]. Inﬂux of phagocytes
in tissues may induce tissue damage (cell dysfunction, apoptosis
or necrosis) via release of oxygen reactive species [25]. All these
features contribute to OFs.
Late stage
A proportion of patients who survive the early stage of bacterial
infections progress to an immune suppressed state [26]. Immune
suppression is characterized by decreased production of inﬂam-
matory cytokines, decreased HLA-DR expression at the surface
of antigen-presenting cells, high risk of hospital-acquired bacteri-
al infections, and infections by reactivated viruses such as cyto-
megalovirus or herpes simplex virus and poor prognosis.
Bacterial infections in cirrhosis. Organ failures related to
immunopathology
Early stage
Evidence for an excessive innate immune response in cirrhosis.
During the ﬁrst hours of bacterial infection, patients with cirrho-
sis have signiﬁcantly higher plasma levels of proinﬂammatory
cytokines than patients without cirrhosis [27]. Experimental
studies investigated the in vivo effects of a challenge with
lipopolysaccharide (LPS, a PAMP recognized by TLR4 (Table 2))
and found that LPS-induced plasma TNF-a levels were
signiﬁcantly higher in cirrhotic than in non-cirrhotic animalsvol. 62 j S131–S143 S135
Table 2. Examples of pattern-recognition receptors (PRRs) and their ligands.⁄
PRRs Localization Ligand Origin of the ligand
Toll-like receptor (TLRs)*
TLR1 Plasma membrane Triacyl lipoprotein Bacteria
TLR2 Plasma membrane Lipoprotein Bacteria, viruses, parasites, self
TLR3 Endolysosome Double-stranded RNA Virus
TLR4 Plasma membrane Lipopolysaccharide Bacteria, viruses, self
TLR5 Plasma membrane Flagellin Bacteria
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses
TLR7 Endolysosome Single-stranded RNA Virus, bacteria, self
TLR8 Endolysosome Single-stranded RNA Virus, bacteria
TLR9 Endolysosome Unmethylated DNA with CpG motifs Virus, bacteria, protozoa, self
TLR10 Endolysosome Unknown Unknown
TLR11** Plasma membrane Profilin-like molecule Protozoa
TLR12** Endolysosome Profilin Protozoa (Toxoplasma gondii)
TLR13** Endolysosome 23S ribosomal RNA Bacteria
Nucleotide binding oligomerization domain (NOD)-like receptors
NOD1 Cytoplasm g-D-glutamyl-mesodiaminopimelic 
acid (iE-DAP)
Bacteria
NOD2 Cytoplasm Muramyl dipeptide (MDP) Bacteria
NLRC4 (IPAF) Cytoplasm Flagellin Bacteria
NAIP5 Cytoplasm Flagellin Bacteria
Retinoic acid-inducible gene (RIG)-I-like receptors
RIG-I Cytoplasm Short double-stranded RNA, 
5’triphosphate double-stranded RNA
RNA viruses, DNA virus, Salmonella 
typhimurium RNA
MDA5 Cytoplasm Long double-stranded RNA RNA viruses
LGP2 Cytoplasm Unknown RNA viruses
C-type lectin receptors
Lectin-1 Plasma membrane β-Glucan Fungi
Lectin-2 (also known as 
CLEC6A)
Plasma membrane β-Glucan Fungi
MINCLE Plasma membrane Unknown Fungi
⁄TLRs form homodimers except TLR2 that can heterodimerize with TLR1 or TLR6.
⁄⁄Expressed in mice but not humans.
Review[28–30]. Interestingly in freshly isolated monocytes or peripheral
blood mononuclear cells (PBMCs), the ex vivo LPS-stimulated pro-
duction of proinﬂammatory cytokines and chemokines is higher
in cells from patients with cirrhosis than in cells from healthy
subjects [23,31–36]. The mechanisms of the ‘‘cytokine storm’’
associated with cirrhosis are poorly understood and need to be
investigated further.
Is there a role for an excessive inﬂammatory response in the
development of organ failures in cirrhosis? In patients with
spontaneous bacterial peritonitis (SBP) higher levels of proin-
ﬂammatory cytokines in the plasma and ascitic ﬂuid are associ-
ated with an increased risk of renal failure [37] The degree of the
ex vivo LPS induction of proinﬂammatory genes in PBMCs from
patients with decompensated cirrhosis is related to prognosis:
the higher the gene induction the higher the risk of short-term
death [23]. ACLF is the main cause of death in patients with
cirrhosis [4]. Together these ﬁndings suggest that patients with
cirrhosis who have innate immune cells with super-inducible
proinﬂammatory genes are at risk of developing ACLF.
Late stage
Evidence of immune suppression has been reported in
some patients with bacterial infection-induced ACLF [38].S136 Journal of Hepatology 2015Patients had decreases in monocyte HLA-DR expression
and ex vivo TNF-a production by LPS-stimulated monocytes
[38]. These ﬁndings suggest that patients were investigated
several days or weeks after their admission to the hospi-
tal, and there is no clear information on the in-hospital
risk of bacterial infection or viral reactivation in patients
with ACLF.Organ failures related to alterations in tissue homeostasis in the general
population and cirrhosis
Direct tissue damage by bacteria
Bacterial virulence can be due to direct damage to host’s
tissues by toxins and virulence factors. Bacterial products
alter tissue homeostasis through different inhibitory mechan-
isms affecting translation, electron transport chain (resulting
in mitochondrial oxidative stress), protein folding in the
endoplasmic reticulum (ER) lumen (resulting in ER stress),
tRNA synthetases, actin cytoskeleton, among others
(Table 3) [19].
There is currently no information on the direct tissue damage
caused by bacteria as a mechanism for OFs in patients with
cirrhosis.vol. 62 j S131–S143
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Failed tolerance
As mentioned earlier, infection may be associated with two ﬁt-
ness costs: ﬁrst, the immune response to infection can be exces-
sive and cause tissue damage; second bacteria can directly
damage tissues [19]. The host can reduce ﬁtness costs through
tolerance mechanisms that reduce tissue damage caused by the
host immune response or directly by bacteria [19]. Some toler-
ance mechanisms are listed in Table 3.
These ﬁndings suggest that failed tolerance can play a role in
the development of OF caused by bacterial infection. To address
this hypothesis Medzhitov and colleagues used a mouse model
of lethal viral (inﬂuenza virus)-bacterial (L. pneumophila) co-
infection [6]. In this model, co-infection results in lung failure
and death. The authors show that lung failure is related to
marked downregulation of a battery of genes including genesPlasma membrane ln 
E. Coli LPS A
Dying cells 
Heat shock proteins 
(HSP60, HSP70, GP96) 
Oxidative stress 
HMGB1 
Ox-
LDL 
TLR2, TLR4, TLR6 
Inflammation 
ECM 
? 
B 
No TNF-α-induced
apoptosis
mRNA
translation 
LPS LPS 
Appropriate
ERUPR
(mild/transient
elF2α
phosphorylation)
Deregulated
ERUPR
Sustained elF2α
phosphorylation
Induction
NF-κB-dependent
antiapoptotic
mRNAs
Induction
NF-κB-dependent
antiapoptotic
mRNAs
NORMAL LIVER CIRRHOTIC LIVER 
TNF-α TNF-α
C 
TLR4
TRAM
TRIF
TRAF3
TRAF6
Type 1 IFN
Pro-inflammatory
IRF3
IKK MAPK
NF-κB AP-1 IRF5
TNF, IL1B, IL6, IL12, IL8, 
CXCL1
TIRAP
MyD88
No mRNA
translation 
TNF-α-induced
APOPTOSIS
Journal of Hepatology 2015involved in tissue and cellular repair and lung development as
well as genes involved in stress responses in lung tissue.
Importantly, in this model there was no evidence for tissue dam-
age caused by the immune response of the host [6]. This is an
example of organ damage cause by failed tolerance.
Little is known about organ tolerance in the context of sepsis
in cirrhosis. In a rat model of LPS-induced sepsis, LPS via TNF-a
induced in vivo apoptosis of 30–40% of hepatocytes in cirrhotic
livers, an effect not observed in normal rats [29]. TNF-a elicited
hepatocyte apoptosis because the translation of NF-jB-survival
genes into proteins was inhibited in these cells [29]. The blockade
of translation of NF-jB-target genes was related to sustained
phosphorylation of eukaryotic initiation factor a caused by
chronic ER stress in cirrhotic hepatocytes [29]. Failed tolerance
may therefore explain LPS-induced hepatocyte death in these cir-
rhotic livers (Fig. 2C).
Inﬂammation unrelated to infection
The trigger of ACLF is not related to an infection in 70% of cases
[1]. In these cases inﬂammation is present and might be induced
by PAMPs or endogenous ligands for TLRs.
Role of PAMPs
Patients with cirrhosis have translocation of intestinal Gram-
negative bacteria [39]. In a proportion of patients whole bacteria
do not reach the systemic circulation and infection does notFig. 2. Induction of inﬂammation and its consequences on hepatocyte
survival in cirrhotic livers. (A) Induction of the innate immune response by
E. Coli lipopolysaccharide (LPS). TLR4, an innate pattern-recognition receptor is
expressed at the surface of immune cells such as monocytes/macrophages. TLR4
recognizes speciﬁcally LPS (a pathogen-associated molecular pattern) and this
recognition results in the early-phase activation of the transcription factor NF-jB
by recruiting the TIR domain–containing adaptors TIRAP (Mal) and MyD88
(MyD88-dependent pathway). MyD88 recruits TRAF6 and induces inﬂammatory
responses by activating NF-jB, MAPK and IRF5. TRAF6 activates the IKK complex
consisting of NEMO and IKKab, which catalyze IjB proteins for phosphorylation.
TLR4 is then internalized and retained in the endosome, where it triggers signal
transduction by recruiting TRAM and TRIF which recruits TRAF6 and TRAF3.
TRAF6 activates MAPK and NF-jB. TRAF3 (with RIP, not shown) activates the
kinases TBK1 and IKKi (not shown), which phosphorylate and activate IRF3, the
last of which controls transcription of type I interferons (IFN). (B) Endogenous
ligands of cell surface TLRs. Molecules released by dying cells, such as high-
mobility group box 1 (HMGB1), heat shock proteins (HSP) and extracellular
matrix (ECM) components are recognized by cell surface TLR2, TLR4 or
TLR2-TLR4. Oxidized low-density lipoproteins (Ox-LDL) are sensed by TLR4-TLR6.
Recognition of these endogenous molecules by cell surface TLRs may lead to
inﬂammation. (C) LPS causes in vivo hepatocyte apoptosis in cirrhotic rat livers.
Left panel: Four hours after LPS challenge normal livers exhibit mild hepatocyte
endoplasmic reticulum (ER) stress and unfolded protein response (ERUPR)
inducing transient phosphorylation of eukaryotic initiation factor (eIF2)-a. LPS
challenge also results in increased tumor necrosis factor (TNF)-a production.
TNF-a engages its cognate receptors (TNF receptor R1, not shown) expressed at
surface of hepatocytes. TNFR1 engagement activates NF-jB which induces a
broad variety of survival mRNA that are translated into proteins. Hepatocyte
accumulation of survival proteins inhibits pro-apoptotic signal encoded by TNF-a.
Right panel: after LPS challenge cirrhotic livers have marked ER stress and ERUPR
resulting in sustained eIF2a phosphorylation. This phosphorylation attenuates
the translation into proteins of most cellular mRNAs, including translation of NF-
jB-dependent survival mRNAs into corresponding proteins. As a result there is no
inhibition of the death signal encoded by TNF-a and hepatocyte apoptosis occurs.
Adapted from reference [29]. TLR, Toll-like receptor; MyD88, Myeloid differen-
tiation primary response protein MyD88; MAPK, mitogen-activated protein
kinase; IRF, IFN-regulatory factor; TRAF, TNFR-associated factor; IKK, IjB kinase;
NEMO, NF-kappa-B essential modulator; TBK1, TANK-binding kinase 1; IjB,
NF-kappa-B inhibitor alpha.
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occur. However these bacteria may release PAMPs that reach the
liver and systemic circulation. PAMPs may thus be recognized by
PRRs and trigger inﬂammation (Table 2). There is evidence of an
LPS contribution to liver inﬂammation and injury in patients with
severe alcoholic hepatitis [40]. The involvement of PAMP-induced
inﬂammation in the development of extra-hepatic OFs deserves
investigation.
Endogenous ligands for TLRs
The fact that TLRs are able to recognize not only PAMPs but also
endogenous molecules (produced by the host) has been shown in
experiments in non-cirrhotic individuals. These molecules can be
released by dying cells and include the danger/damage-associat-
ed molecular pattern (DAMP) high-mobility group box 1
(HMGB1) and products of the extracellular matrix (such as bigly-
can, hyaluronic acid, versican, extradomain A of ﬁbronectin and
surfactant protein A). These endogenous ligands may be recog-
nized by cell surface TLRs (TLR2, TLR4) and induce ‘‘sterile’’
inﬂammation (Fig. 2B) [41]. Dying cells are also known to release
heat shock proteins and some of these proteins have also been
shown to induce inﬂammation through cell surface TLRs [41].
Finally there are examples of TLR-mediated recognition of self
nucleic acids (Table 1). This recognition is inappropriate and
may lead to inﬂammation [28]. Cell death or oxidative stresses
are common ﬁndings in patients with ACLF. Therefore future
studies performed in the context of ACLF should seek for endoge-
nous ligands of TLRs and investigate their role in inﬂammation
and the development of OFs.
ACLF is a complex syndrome because it is the result of a complex
mechanism
The above discussion implies that systemic inﬂammation in ACLF
has a complex pathogenesis. The release of PAMPs by bacteria is
important but the syndrome occurs in the setting of bacterial
infections in only one-third of patients [10]. Translocation of
PAMPs without viable bacteria from the intestinal lumen to the
systemic circulation or the release of DAMPs by dying cells dur-
ing acute liver injury (i.e. acute alcoholic liver injury or reactiva-
tion of hepatitis B) or increased systemic oxidative stress are
likely mechanisms of the ‘‘sterile inﬂammation’’ observed in most
patients with ACLF. Finally, acute increase in systemic inﬂamma-
tion may not be the sole mechanism. It is important to note that
ACLF develops in patients with AD, who already have moderate
systemic inﬂammation and oxidative stress. Direct tissue damage
caused by bacterial products or any process leading to a decrease
in the tolerance to inﬂammation could enhance the effects of this
moderate systemic inﬂammation and precipitate ACLF. These
three mechanisms, which are not mutually exclusive but may
operate simultaneously, could explain many features observed
in patients with AD and ACLF such as the distinct predisposition
to develop ACLF and severity of ACLF between patients in front of
an identical precipitating event (i.e. higher ACLF severity in
patients without prior AD) and the distinct clinical course
(resolution, improvement, steady course or worsening) following
an identical treatment. Also it could account for the effectiveness
of human serum albumin in the prevention and treatment (in
combination with terlipressin) of type-1 HRS, a special form of
ACLF, owing to the capacity of albumin molecule to bind and
decrease the biological effects of PAMPs, vasodilators releasedS138 Journal of Hepatology 2015in systemic inﬂammation (NO and prostaglandins) and reactive
oxygen species.
Key Points 3
• The CLIF-SOFA and its simplified version CLIF-C OF 
scores, which are based in the stratification of the 
function of six organs (liver, kidney, brain, coagulation, 
circulation and respiration) in 5 (0-4) and 3 (1-3) 
subscores, respectively,  (aggregated scores 0-24 
and 3-9, respectively) were initially designed for the 
diagnosis of OF in cirrhotic patients with AD
• Two other specific prognostic scores, one for patients 
with ACLF (CLIF-C ACLF score) and a second for 
patients with AD cirrhosis without ACLF (CLIF-C AD 
score) that improve the prediction accuracy of the 
CLIF-C OF score and CLIF-SOFA, MELD, MELD-Na 
and Child-Pugh scores  were subsequently designed. 
The CLIF-C ACLF score includes the CLIF-C OF score, 
age and white cell count. The CLIF-C AD score includes 
age, white cell count, serum sodium, serum creatinine 
and INR. Variables in each score were combined to 
generate a score system ranging from 0 to 100. The 
CLIF-C OF score, the CLIF-C ACLF score and the 
CLIF-C AD score allow a step-wise algorithm for a 
rational management of patients with decompensated 
cirrhosis
• The general management of ACLF includes a rapid 
identification and treatment of potential triggers, the 
application of measures that prevent progression of 
the syndrome and the use of specific organ support 
systems. In general, patients with ACLF should be 
treated in an ICU environment and potential candidates 
for liver transplantation should be transferred to a 
transplant center. Liver transplantation is treatment 
of choice. One year survival after transplantation is of 
approximately 80%
• Extracorporeal liver support systems based on albumin 
dialysis have been widely used in patients with ACLF. 
They have been shown to be effective in supporting 
organ function in patients with cerebral and renal 
failure. However they did not improve survival. Plasma 
exchange, which increases survival in patients with 
acute liver failure, is being explored in patients with 
ACLF. Finally, studies on the role of bioartificial livers 
using hepatocytes are underway. ACLF represents a 
unique condition to explore the potential effectiveness of 
new treatments such as granulocyte colony-stimulating 
factor or cell (hepatocytes or stem cells) transplantationPrognostic assessment of patients with AD of cirrhosis with
and without ACLF. Therapeutic implications
To develop management strategies for AD patients with or with-
out ACLF, a validated clinical scoring system that can be used at
the bed-side is required that can be updated on a daily basis to
allow on-going stratiﬁcation of patients for intensive care, fast-
track listing for liver transplantation, early hospital discharge or
determination of futility of further intensive care [9,10,15,42].vol. 62 j S131–S143
Table 3. Stresses during infections, their origin and tolerance responses they elicit.
Stress Origin Tolerance response
Fever Host Heat shock factor 1 program
TNF-α-induced cell death Host NF-κB-dependent survival genes
Oxidative stress Host, pathogens NRF2-mediated antioxidant program
Endoplasmic reticulum stress Host, pathogens Unfolded protein response (UPR)
Mitochondrial stress
(inhibition of electron chain transport)
Pathogens Mitochondrial UPR
Inhibition of translation
Ribotoxic stress Pathogens Unknown
tRNA synthetases Pathogens Unknown
Inhibition of actin cytoskeleton Pathogens Serum response factor-mediated program
Tissue hypoxia Host, pathogens Hypoxia inducible factor-1-mediated program
Cell death Host, pathogens Tissue repair program
JOURNAL OF HEPATOLOGYMany previous studies have deﬁned potential prognostic
markers in the cirrhotic patients with OF but for the most part
these studies have not been conducted with a view to deﬁning
prognostic variables, are retrospective, have performed studies
in speciﬁc groups of patients or are not validated in independent
cohorts [15,43–46]. Despite limitations, these previous studies
have pointed to the importance of OF in deﬁning the prognosis
of the sick cirrhotic patients and suggested the importance of sys-
temic inﬂammation. In order to overcome these limitations, one
of the major objectives of the CANONIC Study was to develop a
scoring system for patients with AD of cirrhosis with and without
ACLF and a step-wise algorithm for a rational indication of
therapy.Table 4. Predictive ability of CLIF-C ACLF score (upper panel) and CLIF-C AD score
CANONIC patients with and without Acute-on-Chronic Liver Failure (ACLF), respecti
CLIF-C ACLF score
C-index (95% CI)
Child-Pugh sco
C-index (95% C
CANONIC patients wit
28-day mortality 0.760 (0.715-0.805) 0.668 (0.610-0
p value vs. CLIF-C ACLF score <0.001
90-day mortality 0.732 (0.691-0.773) 0.655 (0.605-0
p value vs. CLIF-C ACLF score <0.001
180-day mortality 0.723 (0.683-0.763) 0.642 (0.593-0
p value vs. CLIF-C ACLF score <0.001
365-day mortality 0.707 (0.668-0.746) 0.636 (0.588-0
p value vs. CLIF-C ACLF score <0.001
CLIF-C AD score
C-index (95% CI)
Child-Pugh sco
C-index (95% C
CANONIC patients witho
90-day mortality 0.743 (0.704-0.783) 0.651 (0.601-0
p value vs. CLIF-C ADs* <0.001
180-day mortality 0.711 (0.675-0.747) 0.635 (0.593-0
p value vs. CLIF-C ADs* <0.001
365-day mortality 0.670 (0.639-0.702) 0.613 (0.578-0
p value vs. CLIF-C ADs* <0.001
Concordance index (C-index) estimates between the observed and predicted mortality p
⁄p values from the IDI statistics test.
Journal of Hepatology 2015Development of a scoring system for patients diagnosed as having
ACLF
The approach used was to perform statistical analysis of clinical
and biochemical factors in the CANONIC patients with ACLF that
were independently associated with mortality and then to
mathematically develop a prognostic model [17]. The factors
independently associated with mortality were the CLIF-C OF
score, age and white cell count. The ﬁnal model including these
three variables was developed to generate a new score (CLIF
Consortium ACLF score, CLIF-C ACLFs), which ranged from 0 to
100. The concordance index as well as the AUC of the ROC curve
showed that this score was signiﬁcantly better at predicting the(lower panel) as compared with MELD, MELD-Sodium and Child-Pugh in the
vely.
re
I)
MELD score
C-index (95% CI)
MELD-Sodium score
C-index (95% CI)
h ACLF (N = 275)
.726) 0.687 (0.635-0.738) 0.684 (0.632-0.736)
<0.001 <0.001
.705) 0.659 (0.615-0.710) 0.663 (0.617-0.709)
<0.001 <0.001
.691) 0.652 (0.607-0.697) 0.654 (0.609-0.699)
<0.001 <0.001
.683) 0.638 (0.595-0.682) 0.640 (0.597-0.683)
<0.001 <0.001
re
I)
MELD score
C-index (95% CI)
MELD-Sodium score
C-index (95% CI)
ut ACLF (N = 1016)
.701) 0.649 (0.602-0.697) 0.681 (0.633-0.728)
<0.001 <0.001
.677) 0.625 (0.585-0.665) 0.655 (0.615-0.695)
<0.001 <0.001
.648) 0.593 (0.560-0.627) 0.618 (0.584-0.652)
<0.001 <0.001
robabilities.
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28-day, 90-day, 180-day and 365-day mortality compared with
the current gold-standards; the Model for End-Stage Liver
Disease score (MELDs) [47], MELD-Sodium score (MELD-Nas)
[48], and the Child-Pugh score (CPs) [49] (Table 4 upper panel,
Fig. 3A and B). The CLIF-C ACLFs was then tested and validated
for sequential use with data obtained from patients at 48-h,
between day 3 and 7 and beyond. The performance of the score
improved signiﬁcantly at predicting 28-day and 3-month mor-
tality of patients when measured at 48 h compared with the mea-
surements at the time of admission suggesting that the CLIF-C
ACLF score can be updated on a daily basis taking into account
the effect of interventions.
Development of a scoring system for patients diagnosed as having
AD but no ACLF
Using a similar approach, the CLIF-C Acute Decompensation score
(CLIF-C ADs) was developed for hospitalized cirrhotic patients
without ACLF using the CANONIC data [50]. The reason for under-
taking this analysis was based on the hypothesis that within theC D 
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Fig. 3. Accuracy of CLIF-C ACLFs and CLIF-C ADs as compared to that of MELDs,
MELD-Nas and CPs in predicting mortality in patients with decompensated
cirrhosis. (A and B) Compares the accuracy of CLIF-C ACLFs with the other scores
in predicting 28-day and 90-day mortality in patients with ACLF. (C and D)
Compares the accuracy of CLIF-C ADs with the other scores in predicting 90-day
and 1 year mortality in patients with acute decompensation of cirrhosis without
ACLF. Accuracy was assessed by estimating the area under the ROC curve
(AUROC) corresponding to each score.
S140 Journal of Hepatology 2015no ACLF patients with AD, there is likely to be a very low risk
group that should be discharged and there may be a high risk
group that will progress to develop full-blown ACLF and therefore
have a high mortality. The analysis revealed ﬁve independent
variables including age, serum sodium, white cell count, creati-
nine and INR. Depending upon the relative weights, they were
combined into a score ranging from 0 to 100. The CLIF-C ADs per-
formed signiﬁcantly better than the MELDs, MELD-Nas, and the
Child-Pugh scores in predicting 3-month and 12-month mortality
(Table 4 lower panel, Fig. 3C and D). In real terms, the CLIF-C ADs
improved prediction of mortality by 10–20% over these other
scoring systems. Additionally, discrete cut-offs were developed
for CLIF-C ADs such that a score of less than or equal to 45 was
associated with a 3-month mortality of 1.8% identifying a very
low risk group. The score also identiﬁed a high risk group that
had a score 60 or above that had a 3-month mortality of about
31%. The intermediate risk group was identiﬁed by a CLIF-C AD
score of greater than 45 but less than 60.
Development of a step-wise algorithm to determine the prognosis of
all hospitalized patients with AD
These three scores speciﬁcally designed for patients with and
without ACLF can be combined into an algorithm that should
be useful in deﬁning the prognosis of cirrhotic patients admitted
to the hospital on a daily basis [50]. CLIF-C OFs scores should be
applied to the patient admitted acutely to the hospital if they
have developed a complication of cirrhosis such as encephalopa-
thy, bleeding, infection or ascites. If the score suggests they have
ACLF, they should be managed in an enhanced care or intensive
care environment. Their prognosis can be determined using the
CLIF-C ACLFs, which can be updated daily. The score can be used
to gauge the effectiveness of intervention or futility within 3–
7 days. On the other hand if they do not have ACLF, then the
CLIF-C ADs should be applied. At the outset, those with CLIF-C
ADs of less than or equal to 45 may be discharged early from
the hospital, those with a score above 60 are at high risk of pro-
gressing to ACLF and should therefore be managed in enhanced
or intensive care, and those with a score greater than 45 but less
than 60 need to be managed in the hospital (Fig. 4). Although the-
se scores are important to allow future studies, there is a scopeAdmission of cirrhotic patient with acute decompensation 
Assess CLIF-C OF score for diagnosis of ACLF 
ACLF present ACLF absent 
CLIF-C AD score 
High risk: 
CLIF-C ADs ≥60
3-month mortality >30%
Intermediate risk: 
CLIF-C ADs 46-59
3-month mortality 2-30%
Low risk: 
CLIF-C ADs ≤45
3-month mortality <2%
CLIF-C ACLF score 
Fig. 4. Algorithm for the sequential use of the EASL-CLIF Consortium
predictive scores in patients with cirrhosis admitted to hospital with acute
decompensation.
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for improvement as the best predictability reached is a C-index in
the range of 0.75.Management of ACLF
General management
The main principle of the general management of patients with
ACLF is an early identiﬁcation of the syndrome and its potential
triggering factors. Although not proven, it is likely that an early
identiﬁcation and treatment of, for example, a SBP in a patient
with cirrhosis and ACLF may have a beneﬁcial impact on patient’s
outcome by preventing/slowing a further progression of ACLF. In
general, patients with ACLF should be treated in enhanced care or
intensive care units for best monitoring and management [42,51].
Potential candidates for transplantation should be transferred to
a transplant centre. Organ function should be monitored fre-
quently and treatment should be given according to each speciﬁc
dysfunction. Circulatory and lung support should be provided if
there is signiﬁcant reduction in arterial pressure and arterial oxy-
genation, respectively. Kidney function should be monitored by
means of urine volume and daily serum creatinine concentration.
In case of circulatory failure or kidney failure, ﬂuid resuscitation
should be performed cautiously to avoid problems related to an
excessive ﬂuid administration such as peripheral edema or, more
importantly pulmonary, edema. A trial of plasma expansion with
albumin or crystalloids should be made for a limited period of
time and then stopped if there is no beneﬁcial effect in terms
of improvement of circulatory or kidney function. It is important
to remark that most patients with cirrhosis and ACLF have
impaired sodium excretion and the ﬂuid administered is usually
retained and may cause signiﬁcant edema and dilutional hypona-
tremia. Brain function should be evaluated frequently and hepat-
ic encephalopathy should be treated promptly. Intubation should
be performed in patients with hepatic encephalopathy grades III
or IV to prevent aspiration. Finally, liver function tests, particular-
ly serum bilirubin and prothrombin time should be measured
daily.
Speciﬁc management
In this section, the potential usefulness of some therapeutic
options is discussed in the light of the available evidence.
Liver transplantation
Liver transplantation is a useful method for treating patients with
ACLF [52–54]. Nonetheless, it should be noted that not all
patients with ACLF are transplant candidates for a number of rea-
sons, which may include advanced age, active alcoholism, or con-
comitant diseases, and that the presence of associated OFs,
particularly if the number is high or they are severe, may pre-
clude transplantation, at least for a certain period of time until
multiorgan dysfunction has improved. Available information on
liver transplantation for ACLF patients’ is limited [52–54]. One
year survival after transplantation is of approximately 80%,
slightly lower but not signiﬁcantly different from that of patients
transplanted without ACLF. However, published studies are retro-
spective, have a limited sample size, and have used variable
deﬁnitions of ACLF. Most importantly, only one study used inten-
tion-to-treat analysis and showed that some potential candidatesJournal of Hepatology 2015are not even listed for transplantation and out of those listed
mortality is of 50% [54]. Overall, only one-third of potential can-
didates reach liver transplantation according to this report. There
is therefore a clear need for effective therapeutic methods that
can ‘‘bridge’’ patients with ACLF to liver transplantation.
Extracorporeal liver support systems
In recent years, several extracorporeal liver support systems have
been assessed in the management of ACLF [6,55–57]. These sys-
tems are based on dialysis techniques aimed at removing a num-
ber of substances thought to participate in the pathogenesis of
ACLF, such as NO, prostaglandins, PAMPs and reactive oxygen
species. The most extensively used system, is the extracorporeal
albumin dialysis by the molecular adsorbent recirculating system
(MARS). Besides reducing the plasma levels of a number of sub-
stances, it has been shown that MARS is effective in improving
systemic hemodynamics and severe hepatic encephalopathy.
However, a randomized multicentre European study of MARS
vs. standard therapy in 189 patients with ACLF did not show dif-
ferences in survival [57]. Another randomized study using a dif-
ferent system, Prometheus, also showed no improvement on
survival [58]. Therefore, although these systems have some
beneﬁcial effects in patients with ACLF, their overall usefulness
in this setting is uncertain. Along the lines of dialysis systems,
plasma exchange has also been proposed as a therapeutic method
in patients with acute liver failure and ACLF. A randomized study
in patients with acute liver failure showed improved survival in
patients treated with plasma exchange compared to a control
group receiving standard therapy [59]. A study in patients with
ACLF organized by the EASL-CLIF Consortium is underway.
Other methods
A few recent studies have focused their attention on the potential
effectiveness of granulocyte colony-stimulating factor (C-CSF) in
patients with ACLF [60–62]. Two randomized studies, one per-
formed mainly in alcoholic patients and the other exclusively in
patients with chronic HBV infection, have shown that administra-
tion of G-CSF to patients with ACLF reduces the risk of developing
kidney and brain failure, and sepsis and improves short-term sur-
vival [60,61]. It is important to note that patients with sepsis,
multiorgan failure and/or grade 3 or 4 hepatic encephalopathy
were excluded from these studies, which indicates that most of
the treated patients had ‘‘early’’ ACLF. Potential treatment effec-
tiveness may be related to the mobilization of CD34+ cells from
bone marrow to the liver, improvement of neutrophil function,
or some other yet unknown factors.
Finally, cell transplantation, either using hepatocytes or stem
cells, has also been proposed as potential therapy for patients
with ACLF with the aim of improving liver function by causing
cell repopulation of the diseased liver [63–68]. Moreover, mes-
enchymal stem cells have a number of other potentially beneﬁ-
cial effects, including anti-inﬂammatory actions. So far,
however, the available information is limited and a deﬁnite con-
clusion about its potential efﬁcacy in clinical practice cannot be
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